Blog Tag
3 articles tagged with Competition. The newest post is from Mar 2, 2026.
A patent cliff is the point at which a drug loses patent protection or market exclusivity and faces sharp competition from generic or biosimilar alternatives. In biotech and pharma, the patent cliff matters because it can cause a large drop in revenue when competitors enter the market. Investors watch it closely because it can dramatically change future earnings expectations.
A biosimilar is a biologic product that is highly similar to an already approved reference biologic, with no clinically meaningful differences in safety, purity, or potency. In biotech, biosimilars matter because they introduce competition into biologic markets that were once protected by exclusivity and patent strength.
A biosimilar is a biologic product that is highly similar to an already approved reference biologic, with no clinically meaningful differences in safety, purity, or potency. In biotech, biosimilars matter because they introduce competition into biologic markets that were once protected by exclusivity and patent strength.
